FLASH Biomarker Study

November 12, 2026 updated by: Abramson Cancer Center at Penn Medicine

Biomarker Characterization in Patients Undergoing Ultra-High Dose Rate (ConformalFLASH®) on the C-FLASH-01 Trial

This is a single-center, non-interventional biospecimen collection protocol that accompanies C-FLASH-01 (Protocol IBA-04-UP, IDE G260113), a pilot trial of ultra-high dose rate proton reirradiation (ConformalFLASH) for head and neck cancer. Blood and saliva will be collected from up to 10 participants enrolled on the C-FLASH-01 trial at three time points: 1) within 4 weeks before the start of radiotherapy, 2) within 3 days of the last day of radiotherapy, and 3) within 4 months after completion of radiotherapy.

Study Overview

Status

Not yet recruiting

Detailed Description

The study team hypothesize that biomarkers measurable in blood and saliva, including but not limited to cell-free DNA and cytokines, change over the course of ConformalFLASH reirradiation and are associated with normal tissue response/toxicity. This protocol does not include a study intervention; all radiotherapy is delivered under the separately approved parent protocol (Protocol IBA-04-UP, IDE G260113).

Study Type

Observational

Enrollment (Estimated)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants are recruited exclusively from among individuals enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) in the Department of Radiation Oncology at the University of Pennsylvania. No advertising, flyers, social media, or other external recruitment will be used, and no additional screening of the general population is required.

Description

Inclusion Criteria:

  • Enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) and planned to receive ConformalFLASH reirradiation
  • Male or female, aged 18 years or older
  • Provision of signed and dated informed consent for this biospecimen protocol
  • Stated willingness to comply with the specimen collection

Exclusion Criteria:

  • Any condition that, in the judgment of the investigator, makes repeated peripheral venipuncture unsafe or infeasible
  • Inability to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: OTHER
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Batched analysis of Biomarker dynamics in blood Including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.
Time Frame: - Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)

Change in biomarker measures (e.g., cell-free DNA and cytokines) in plasma between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy.

At each time point, 16 mL of peripheral blood will be drawn by a trained phlebotomist or delegated study team member into Streck Cell-Free DNA BCT tubes and EDTA tubes. The maximum cumulative volume drawn under this protocol is 48 mL per participant. Streck tubes stabilize cell-free DNA for the cell-free DNA analyses; EDTA tubes provide plasma and buffy coat for cytokine analyses and potential cellular analyses.

At every collection - blood will be centrifuged; plasma and buffy coat aliquoted and stored at - 80 °C.

- Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)
Batched analysis of Biomarker dynamic in the saliva including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.
Time Frame: - Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)

Change in biomarker measures (e.g., cell-free DNA and cytokines) in saliva between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy.

At each time point, saliva will be collected into a commercial saliva collection tube in accordance with the manufacturer's instructions, after the 30-minute interval.

At every collection - Saliva will be stored at - 80 °C.

- Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shervin Tabrizi, MD, University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2029

Study Completion (Estimated)

November 1, 2029

Study Registration Dates

First Submitted

October 30, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UPCC 16326
  • 26-8473 (Other Identifier: University of Pennsylvania, Internal Review Broad (IRB))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe